Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

Liver Transplantation - Tập 21 Số 6 - Trang 823-830 - 2015
Julio Gutiérrez1,2, Andres F. Carrion1, Danny J. Avalos1, Christopher O’Brien1, Paul Martin1, Kalyan Ram Bhamidimarri1, Adam Peyton1
1Division of Hepatology,Miller School of Medicine,University of Miami,Miami,FL
2Texas Liver Institute,Health Science Center,University of Texas,San Antonio,TX

Tóm tắt

Recurrent hepatitis C virus (HCV) infection occurs universally in the allograft in the absence of effective antiviral therapy before liver transplantation (LT). Antiviral therapy with sofosbuvir and simeprevir has proven to be highly effective and well tolerated in the nontransplant setting for treatment of HCV genotype 1 infection; therefore, we sought to evaluate the efficacy and safety of this regimen in LT recipients with recurrent HCV infection. This was a retrospective analysis of a single‐center treatment protocol of patients with HCV genotype 1 infection who received a 12‐week combination regimen of sofosbuvir and simeprevir. Sixty‐one patients (35 with genotype 1a and 26 with genotype 1b) completed treatment with simeprevir and sofosbuvir. Three patients received additional ribavirin. Laboratory data and clinical assessments performed at the baseline, on treatment, at the end of treatment, and 12 weeks after the completion of antiviral therapy [sustained virological response at 12 weeks (SVR12)] were analyzed. The median time after LT was 5.4 years [interquartile range (IQR), 1.9‐8.4 years], and tacrolimus was the most commonly used immunosuppressive agent (80.3%). Overall, SVR12 was achieved in 93.4% [95% confidence interval (CI), 84%‐97%] of LT recipients treated with 12 weeks of sofosbuvir and simeprevir. When they were analyzed according to the HCV subtype, LT recipients with genotype 1b had a 100% SVR12 rate (95% CI, 87%‐100%), whereas SVR12 was 89% (95% CI, 74%‐95%) for those with genotype 1a. Advanced fibrosis (METAVIR F3‐F4) was associated with diminished antiviral efficacy in LT recipients with genotype 1a [SVR12, 67% (95% CI, 39%‐86%); P = 0.01]. Overall, the incidence of adverse events (AEs) was low, and no severe AEs occurred during treatment. In conclusion, treatment with a 12‐week regimen of sofosbuvir and simeprevir was well tolerated and resulted in a high SVR12 rate for LT recipients with recurrent HCV genotype 1 infection. Genotype 1a patients with advanced fibrosis of the allograft were more likely to relapse. Liver Transpl 21:823‐830, 2015. © 2015 AASLD.

Từ khóa


Tài liệu tham khảo

2009, Diagnosis, management, and treatment of hepatitis C: an update, Hepatology, 49, 1335, 10.1002/hep.22759

2008, The impact of disease recurrence on graft survival following liver transplantation: a single centre experience, Transpl Int, 21, 459, 10.1111/j.1432-2277.2007.00628.x

2013, Progression of liver fibrosis in post‐transplant hepatitis C: mechanisms, assessment and treatment, J Hepatol, 58, 1028, 10.1016/j.jhep.2012.12.014

2009, The natural history of hepatitis C cirrhosis after liver transplantation, Liver Transpl, 15, 1063, 10.1002/lt.21784

2002, The association between hepatitis C infection and survival after orthotopic liver transplantation, Gastroenterology, 122, 889, 10.1053/gast.2002.32418

2007, Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study, Gastroenterology, 132, 1746, 10.1053/j.gastro.2007.03.041

2012, Antiviral therapy and fibrosis progression in patients with mild‐moderate hepatitis C recurrence after liver transplantation. A randomized controlled study, Dig Liver Dis, 44, 603, 10.1016/j.dld.2012.01.017

2008, Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin, J Hepatol, 49, 274, 10.1016/j.jhep.2008.05.002

2014, Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience, J Hepatol, 60, 78, 10.1016/j.jhep.2013.08.018

2013, Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation, Liver Transpl, 19, 690, 10.1002/lt.23669

2014, Protease inhibitor‐based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience, Ann Hepatol, 13, 525, 10.1016/S1665-2681(19)31252-9

2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853

2014, Sofosbuvir and ribavirin in HCV genotypes 2 and 3, N Engl J Med, 370, 1993, 10.1056/NEJMoa1316145

2013, Sofosbuvir in combination with peginterferon alfa‐2a and ribavirin for non‐cirrhotic, treatment‐naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double‐blind, phase 2 trial, Lancet Infect Dis, 13, 401, 10.1016/S1473-3099(13)70033-1

2014, Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐1): a phase 3, randomised, double‐blind, placebo‐controlled trial, Lancet, 384, 403, 10.1016/S0140-6736(14)60494-3

2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐2): a randomised, double‐blind, placebo‐controlled phase 3 trial, Lancet, 384, 414, 10.1016/S0140-6736(14)60538-9

2014, Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial, Gastroenterology, 146, 1669, 10.1053/j.gastro.2014.02.051

2015, Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation, Gastroenterology, 148, 108, 10.1053/j.gastro.2014.10.001

2014, Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non‐responders to pegylated interferon and ribavirin and treatment‐naive patients: the COSMOS randomised study, Lancet, 384, 1756, 10.1016/S0140-6736(14)61036-9

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant., Hepatology 2015

2007, Management of hepatitis C infection after liver transplantation, Drugs, 67, 871, 10.2165/00003495-200767060-00004

2008, The natural history of recurrent hepatitis C and what influences this, Liver Transpl, 14, S36

2000, Natural history of clinically compensated hepatitis C virus‐related graft cirrhosis after liver transplantation, Hepatology, 32, 852

2014, Recurrent HCV after liver transplantation‐mechanisms, assessment and therapy, Nat Rev Gastroenterol Hepatol, 11, 710, 10.1038/nrgastro.2014.114

2007, Fibrosis progression in hepatitis C positive liver recipients after sustained virological response to antiviral combination therapy (interferon‐ribavirin therapy), Transplantation, 83, 351, 10.1097/01.tp.0000250575.92788.aa

2004, Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C, Liver Transpl, 10, 199, 10.1002/lt.20074

2002, Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C, Liver Transpl, 8, 1000, 10.1053/jlts.2002.34968

Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation, Hepatol Res

2013, Drug‐drug interactions during antiviral therapy for chronic hepatitis C, Nat Rev Gastroenterol Hepatol, 10, 596, 10.1038/nrgastro.2013.106

2014, An interferon‐free antiviral regimen for HCV after liver transplantation, N Engl J Med, 371, 2375, 10.1056/NEJMoa1408921

Thông tin
Thông tin xuất bản

Liver Transplantation

Tập 21 Số 6

823-830

Thông tin tác giả